NEW YORK – The UK's National Institute for Health and Care Excellence on Tuesday recommended Bristol Myers Squibb's immunotherapy combination Opdivo (nivolumab) and Yervoy (ipilimumab) as a first-line ...

The firms will explore molecular mechanisms and patient responses in cancer to inform development of new therapies.

Interim results from a Phase III trial showed the combo benefited HER2-positive metastatic breast cancer patients in the first-line setting.

Trodelvy combo improved progression-free survival in patients with PD-L1-positive tumors compared to Keytruda-chemo.

This small branch played a big role in advancing evidence-based genetic testing, and its loss diminishes US leadership in ...

Ono has an exclusive option to discover, develop, and commercialize drug candidates based on RNA-editing drug sequences designed by Jorna.

The firms will use nFerence's Agentic AI platform to analyze real-world treatment patterns in 700 patients' charts and inform personalized care.

The tool analyzes results from standard tests of organ function, tumor burden, and inflammation to predict whether lymphoma patients will respond to treatment.

A federal district court had ruled in favor of HHS, restricting Vertex's ability to provide fertility preservation services to Medicaid patients.